
## Rare and Neglected Diseases Pieces of the Puzzle

Bonny Harbinger, Ph.D., J.D. Deputy Director Office of Technology Transfer National Institutes of Health U.S. Department of Health & Human Services


ICORD -2008



### NIH Intramural Research Program

- 6,000 intramural scientists
- 2,000 active projects
- Basic & clinical research discoveries
- Collaborations with industry & academia
- 224 Rare disease related technologies
- ~ 1,400 technologies available for licensing
- ~200 products developed to date (24 vaccines and therapeutics)





	Participants	
Rare	Baystate Health System	
	Beth Israel Deaconess Medical Center Boston Biomedical Research Institute	
	Boston University	
<ul> <li>Webs</li> </ul>	Brigham and Women's Hospital	
• Host:	Children's Hospital Dana-Farber Cancer Institute	
	Harvard University	
OTT	Joslin Research Massachusetts Eye and Ear Infirmary	
_	$\mathbf{r}$	
<ul> <li>Partic</li> </ul>	National Jewish Medical & Research Center	
	St. Jude Children's Research Hospital The CBR Institute for Biomedical Research	
OTT	The University of British Columbia	
	Tufts University	
<ul> <li>VISITO</li> </ul>	University of Arizona University of Arkansas for Medical Sciences	
Licen	University of California, Davis University of California, Los Angeles	
	University of Massachusetts University of Rochester Medical Center	· 👘 🖕
	Yeda R&D Co. Ltd.	
STER		



#### **Rare Diseases and Conditions**

#### Technologies Available for Licensing from NIH/FDA and Non-Profit Institutions

Technologies related to rare diseases or conditions available for commercial licensing are listed under the related disease or condition. You can search disease names alphabetically or by specific name. Note that, at present, there may not be a listed invention for every disease or condition. Please continue to revisit the site as it will be updated periodically. The diseases and conditions on the site are those designated as such by the NIH Office of Rare Diseases and are defined as having a prevalence of fewer than 200,000 affected individuals in the US. For background information on a specific disease or condition, please visit the <u>NIH</u> <u>Office of Rare Diseases Website</u> or click on the <u>[Define]</u> button next to the disease name.

If you are a non-profit institution and would like to have your technology included in this list, please Click Here.

#### AIBICIDIEIEIGIHIIIJIKILIMINIOIPIQIRISITIUIVIWIXIYIZI<u>[1-9]</u>IAII

- Acoustic neuroma [Define]
- Acute lymphoblastic leukemia, Childhood [Define]
- Acute respiratory distress syndrome [Define]
- Adenocarcinoma of lung [Define]
- Adrenal cancer [Define]
- Albinism [Define]
- Alpha 1-antitrypsin deficiency [Define]
- Alzheimer disease type 1 [Define]
- <u>Amyloidosis</u> [Define]
- Anaplastic large cell lymphoma [Define]
- Anthrax [Define]
- <u>Ataxia telangiectasia</u> [Define]
- <u>Autoimmune myocarditis</u> [Define]

- Actinomycetales infection [Define]
- Acute myelogenous leukemia [Define]
- Addison's disease [Define]
- Adenosine deaminase deficiency [Define]
- Adrenocortical carcinoma [Define]
- <u>Alkaptonuria</u> [Define]
- Alpha-Thalassemia [Define]
- Alzheimer disease type 2 [Define]
- <u>Amyotrophic lateral sclerosis</u> [Define]
- Aneuploidy [Define]
- Aplastic anemia [Define]
- <u>Autoimmune hepatitis</u> [Define]







Technologies Available for Licensing from NIH/FDA

Preeclampsia

#### Determination of AM-Binding Proteins and the Association of Adrenomedullin (AM) Therewith

The present invention provides methods for the isolation, identification, and purification of adrenomedullin (AM)- binding proteins. Methods for utilizing the purified AM-binding proteins, or functional portions thereof, to diagnose, treat, and monitor AM-related diseases are described. A second aspect of this technology discloses the identification and isolation of a novel complex between AM and a specific AM-binding protein 1 (AMBP-1), design... More ....

#### The Many Roles Of Adrenomedulin In Human Pathology And Physiology

Adrenomedullin (AM) is an a-amidated 52-amino acid peptide that shows slight similarity to calcitonin gene-related peptide (CGRP). The effects of AM and its fragments in the cardiovascular system have been widely studied. Endothelial cells secrete the peptide that acts on specific receptors present in the vascular smooth muscle cells and other contractile cells. Some diuretic functions have been also described. In the respiratory system, two majo... More ...

<u>Method Evolved for Recognition of Thrombophilia (MERT): Clinical Predictive Genetic Test for Venous</u> <u>Thrombosis</u>

Venous thrombosis (VT) is one of the leading causes of mortality and morbidity resulting in approximately 300,000 hospitalizations and 50,000 fatalities per year in the United States with an incidence of 141 per 100,000 African-Americans, 104 per 100,000 Caucasians and 21 per 100,000 Asian/Pacific Islanders. However, it is an avoidable disease if effective preventive measures such as early thromboprophylaxis are instituted.

It is hig... More ...

#### Technologies Available for Licensing from Non-Profit Institutions

University of California, Davis

DIAGNOSTIC IMMUNOASSAY FOR HYPERTENSION, ARDS, CARDIOVASCULAR DISEASE, AND LIPID DISORDERS

Boston Biomedical Research Institute, Watertown, MA

Leptin Peptide Antagonists for cancer, endometriosis, preeclampsia and fertility regulation

Children's Hospital, Boston, MA

Methods And Compositions For Treatment Of Preeclampsia And Other Pregnancy Complications.





#### AIBICIDIEIEIGIHIIIJIKI LIMINIOIPIQIRISITIUI VIWIXIYIZI[1-9]IAII

- Overview
- Pagets disease
- <u>Pancreatic islet cell</u> <u>tumors</u>
- Papillitis
- Parainfluenza virus type 3
- Paraplegia
- Parvovirus antenatal infection
- Pasteurella multocida
- Pemphigus
- Pemphiqus vulgaris
- Pendred syndrome
- Peripheral neuropathy
- Peripheral T-cell lymphoma
- Pheochromocytoma
- Pick disease of t
- Plaque
- Pneumoconiosis
- Poliomyelitis
- <u>Polyarthritis</u>
- Polyomavirus Infections
- > Precocious pube
- Preeclampsia
- Premature agine

Technologies Available for Licensing from NIH/FDA

#### Preeclampsia

#### Determination of AM-Binding Proteins and the Ass

The present invention provides methods for the isolation, identif for utilizing the purified AM-binding proteins, or functional portio described. A second aspect of this technology discloses the id AM-binding protein 1 (AMBP-1), design... More ...

#### The Many Roles Of Adrenomedulin In Human Path

Adrenomedullin (AM) is an a-amidated 52-amino acid peptide : effects of AM and its fragments in the cardiovascular system h specific receptors present in the vascular smooth muscle cells described. In the respiratory system, two majo ... More ...

#### Method Evolved for Recognition of Thrombophilia Thrombosis

Venous thrombosis (VT) is one of the leading causes of mortal 50,000 fatalities per year in the United States with an incidence 21 per 100,000 Asian/Pacific Islanders. However, it is an avoid thromboprophylaxis are instituted.

It is hig... More ....

Technologies Available for Licensing from Non-Prof

#### University of California, Davis

DIAGNOSTIC IMMUNOASSAY FOR HYPERTENSION, ARDS, CARDIOVASCULAR DISEASE, AND LIPID DISORDERS


Boston Biomedical Research Institute, link: DIAGNOSTIC IMMUNOASSAY FOR HYPERTENSION, ARDS, CARDIOVASCULAR DIS...

Leptin Peptide Antagonists for cancer, endometriosis, preeclampsia and fertility regulation

Children's Hospital, Boston, MA

Methods And Compositions For Treatment Of Preeclampsia And Other Pregnancy Complications.





### **Neglected Diseases**

#### CIENCE, IDEAS, BREAKTHROUGHS

#### Neglected Diseases

#### Technologies Available for Licensing from NIH/FDA and Non-Profit Institutions

Global health organizations define neglected diseases as those that are prevalent among impoverished and marginalized populations in the developing world. Tropical environments, poor conditions, and limited access to health care contribute to the risk and spread of these diseases,

Technologies related to neglected diseases available for commercial licensing can be viewed by clicking on the disease of interest. The list is a compilation of diseases recognized as negl the World Health Organization. Note that, at present, there may not be a listed invention for every disease. Please continue to revisit the site as it will be updated periodically. For additional in: on a specific disease, click on the [Define] link.

If you are a non-profit institution and would like to have your technology included in this list, please Click Here.

#### **Bacterial Infections**

- Buruli ulcer (Mycobacterium ulcerans) [Define]
- Leprosy (Mycobacterium leprae) [Define]
- Tuberculosis (Mycobacterium tuberculosis) [Define]

- Cholera (Vibrio cholerae) [Define]
- Trachoma (Chlamydia trachomatis) [Define]
- Yaws (Treponema pertenue) [Define]

#### Helminthic Infections

- Dracunculiasis [Guinea-worm disease] (Dracunculus medinensis) [Define]
   Fascioliasis (Fasciola sp.) [Define]
- Hookworm (Ancylostoma duodenale, Necator americanus) [Define]
- Onchocerciasis [River blindness] (Onchocerca volvulus) [Define]
- Schistosomiasis [Bilharzia or snail fever] (Schistosoma sp.) [Define]
- **Protozoan Infections**
- African Trypanosomiasis [Sleeping sickness] (Trypanosoma brucei) [Define] 
   Chagas disease (Trypanosoma cruzi) [Define]
- Leishmaniasis (Leishmania sp.) [Define]

Lymphatic filariasis [Elephantiasis] (Wuchereria bancrofti, Brugia malavi)

TUN NIN STATE

Roundworm (Ascaris lumbricoides) [Define]

Whipworm (Trichuris trichiura) [Define]

Malaria (Plasmodium sp.) [Define]

#### **Viral Infections**

Denque (Flaviviridae) [Define]

Rotavirus (Reoviridae) [Define]

### **OTT RD Statistics**

- Number of RD on site: 290
- Number of External Institutes: 24
- Number of External Technologies: 182





VIH Office of Technology Transfer

# Thank you!


Bonny Harbinger, Ph.D., J.D. Deputy Director Office of Technology Transfer (OTT) National Institutes of Health 6011 Executive Boulevard Suite 325, Mail Stop 7660

Rockville, MD 20852-3804 (301) 435-2843 harbingb@mail.nih.gov Stephen C. Groft, Ph.D. Director Office of Rare Diseases (ORD) National Institutes of Health

6100 Executive Boulevard Room 3B01, Mail Stop 7518 Bethesda, MD 20892-7518 (301) 402-4336 ord@mail.nih.gov



### www.ott.nih.gov/rd



### Science. Ideas. Breakthroughs.